DanielAlexanderLaheruMD

Gastrointestinal Cancer, Hematologic Oncology

Professor of Oncology, Johns Hopkins University School of Medicine; Co-Director, Skip Viragh Center for Pancreas Cancer, Ian T. MacMillan Professorship in Clinical Pancreatic Cancer Research

Join to view full profile

Dr. Laheru is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Laheru's full profile

Already have an account?

Office
10803 Falls Road
Pavilion Iii Ste 1500
Lutherville, MD 21093
Phone+1 410-583-2970

Fax+1 410-583-2980

Summary

Dr. Daniel Laheru is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He received his medical degree from Baylor College of Medicine and has been in practice 22 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in gastrointestinal oncology, general medical oncology, and pancreatic cancer, immunotherapy.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Utah HealthResidency, Internal Medicine, 1995 - 1998
Baylor College of MedicineClass of 1995

Certifications & Licensure

MD State Medical License 1998 - 2026
VA State Medical License 2024 - 2026
PA State Medical License 2020 - 2024
NC State Medical License 2020 - 2022
UT State Medical License 1996 - 2004
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Join now to see all

Clinical Trials

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer Start of enrollment: 2005 Oct 01
Terminated
Phase 2
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer Start of enrollment: 2005 Dec 01
Completed
Phase 2
Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer Start of enrollment: 2006 Sep 11
Completed
Phase 2
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2008 Jul 02
Completed
Phase 2
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants Start of enrollment: 2005 May 01
Completed
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1, Phase 2
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Start of enrollment: 2010 Sep 17
Completed
Phase 2
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors Start of enrollment: 2006 Apr 01
Completed
Phase 1
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma Start of enrollment: 2013 Jan 01
Active, not recruiting
Phase 2
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Start of enrollment: 2018 Jan 05
Terminated
Phase 1
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer Start of enrollment: 2018 Feb 02
Completed
Phase 2
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) Start of enrollment: 2018 May 14
Completed
Phase 1
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer Start of enrollment: 2018 Aug 10
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

4433 citations
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante
The New England Journal of Medicine. 2013-10-30
366 citations
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Eric R. Lutz, Annie A. Wu, Elaine Bigelow, Rajni Sharma, Guanglan Mo
Cancer Immunology Research. 2014-07-01
5 citations
Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer.
Channing J Paller, Lin Wang, Wei Fu, Rajendra Kumar, Jennifer N Durham
Cancer Research Communications. 2023-02-01

Journal Articles

Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy
Alex B Blair, Joseph Herman, Martin Makary, John L Cameron, Amol Narang, Daniel Laheru, Christopher Wolfgang, Matthew J Weiss, Ammar A Javed, Jin He, Journal of gastrointestinal surgery